Observational Prospective study to esTIMAte the rates of outcomes in patients undergoing PCI with drug-eluting stent implantation who take statins –follow-up (OPTIMA II)

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Medical Research and Opinion

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/03007995.2016.1253552PMID 27779436
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

  2016cited by this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention

  2016cited by this paper
• High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention.

  2016cited by this paper
• Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000 patients.

  2014cited by this paper
• Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• ЦЕНТРАЛИЗОВАННОЕ ИССЛЕДОВАНИЕ ПО ОЦЕНКЕ ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ В РОССИИ (CEPHEUS)

  2013cited by this paper
• Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care

  2013cited by this paper
• ESC/EAS Guidelines for the Management of Dyslipidaemias

  2013cited by this paper
• [Prognostic value of markers of inflammation in patients with stable ischemic heart disease after implantation of stents with drug covering at the background of long-term therapy with statins (inhospital period)].

  2012cited by this paper
• Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries.

  2012cited by this paper
• Abstract 9356: Pre-procedure C-reactive Protein and Erythrocyte Sedimentation Rate but not Lipoprotein-associated Phospholipase A2 Predict Clinical Outcomes after Drug-eluting Stents Implantation in Patients with Stable Coronary Disease on Chronic Statin Therapy

  2012cited by this paper
• Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry

  2012cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2011cited by this paper
• Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies

  2011cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Supplementary webappendix

  2009cited by this paper
• Beneficial effects of statins after percutaneous coronary intervention

  2009cited by this paper
• Recapturing the magic: revisiting the pleiotropic effects of statins in percutaneous coronary revascularization.

  2009cited by this paper
• European cardiovascular disease statistics

  2008cited by this paper
• Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease

  2007cited by this paper
• Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2006cited by this paper
• Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.

  2006cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Beneficial Cardiovascular Pleiotropic Effects of Statins

  2004cited by this paper
• Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study

  2004cited by this paper
• Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction.

  2004cited by this paper
• C-reactive protein and coronary events following percutaneous coronary angioplasty.

  2003cited by this paper
• Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

  2003cited by this paper
• Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease.

  2003cited by this paper
• Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions

  2003cited by this paper
• C-reactive protein predicts death in patients with previous premature myocardial infarction--a 10 year follow-up study.

  2002cited by this paper
• C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina.

  2002cited by this paper
• Preprocedural Statin Medication Reduces the Extent of Periprocedural Non–Q-Wave Myocardial Infarction

  2002cited by this paper
• Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction

  2002cited by this paper
• Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention

  2002cited by this paper
• Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

  2001cited by this paper
• Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆

  2001cited by this paper
• Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention

  2001cited by this paper
• Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation.

  2001cited by this paper
• Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels

  2001cited by this paper
• Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

  2001cited by this paper
• Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia

  2001cited by this paper
• Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

  1997cited by this paper
• Letter: Grading of angina pectoris.

  1976cited by this paper
• THE WORLD HEALTH ORGANIZATION

  1954cited by this paper

• Assessing the timing of invasive intervention in NSTE-ACS: insights from a meta-analysis and sequential trial evaluation

  2025cites this paper